July 13, 2012Journal of Hypertension
L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease
Why the study?
Does L-carnitine supplementation prevent ventricular fibrosis and heart failure with preserved ejection fraction in a hypertensive heart disease model?
Population
Dahl salt-sensitive rats fed high-salt diet, cultured cardiac fibroblasts, and HFpEF patients
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Does not support L-carnitine use in HFpEF; leaves open therapeutic potential in hypertensive models pending human trials.
Structured PICO
Does L-carnitine supplementation prevent ventricular fibrosis and heart failure with preserved ejection fraction in a hypertensive heart disease model?
P
Population
Dahl salt-sensitive rats fed high-salt diet (model of hypertensive HFpEF), cultured cardiac fibroblasts, and HFpEF patients
I
Intervention
L-Carnitine
O
Outcome
Left-ventricular fibrosis, stiffening, pulmonary congestion, and survivalsurrogate
L-carnitine supplementation attenuates cardiac fibrosis and improves survival in a rat model of hypertensive HFpEF by increasing prostacyclin production, suggesting a potential therapeutic option.
Cite This Study
Ohtani et al. (2012) studied this question.